Penelope Bradbury
机构: University of Toronto
每年引用次数
引用次数
引用: 4,161
H-指数: 36
I10-指数 : 75
出版物: 307
Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins.
T T Zhao , B G Le Francois , G Goss , K Ding
Oncogene 29 ( 33) 4682 -4692
48
2010
Real World Outcomes of Prophylactic Cranial Irradiation Utilization and Efficacy for Patients with Extensive-Stage Small Cell Lung Cancer Treated with Consolidative Thoracic Radiotherapy
Abdul Haadee Lone , Rohan Salunkhe , Vijithan Sugumar , Luna Jia Zhan
Writing the Protocol
PENELOPE A BRADBURY , ELIZABETH A EISENHAUER
Phase I Cancer Clinical Trials: A Practical Guide 200 -200
2015
Feasibility of collecting routine information for clinical and research purposes via electronic format questionnaire.
Yuchen Li , M Catherine Brown , Kathryn Estey , Gursharan Gill
Journal of Clinical Oncology 35 167 -167
2017
Health utility scores (HUS) and health-related quality of life (HRQoL) in stage 4 lung cancer (S4LC) patients with brain metastases (BM).
Vivian Tam , Brandon C Tse , Tiffany Tse , Lin Lu
Journal of Clinical Oncology 35 24 -24
1
2017
The impact of neurocognitive function on health utility scores (HUS) in Stage 4 (S4) lung cancer patients (pts) with and without brain metastases (BrM).
Brandon C Tse , Vivian Tam , Tiffany Tse , Lin Lu
Journal of Clinical Oncology 35 ( 5_suppl) 225 -225
2017
A Randomized Phase II study of Reolysin in Patients with Previously Treated Advanced or Metatstatic Non Small Cell Lung Cancer (NSCLC) receiving Standard Salvage Chemotherapy – Canadian Cancer Trials Group IND 211.
Donald Morris , Dongsheng Tu , Mustapha Ali Tehfe , Garth Andrew Nicholas
Journal of Clinical Oncology 34
3
2016
Effect of brain metastases on survival and systemic treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC).
Mark Doherty , Grzegorz Korpanty , Pascale Tomasini , Moein Alizadeh
Journal of Clinical Oncology 34
1
2016
The economic impact of the transition from branded to generic oncology drugs.
Winson Y. Cheung , Nicole Mittmann , Natasha B. Leighl , Matthew C. Cheung
Journal of Clinical Oncology 34 6520 -6520
2016
Real-world EQ5D health utility values for metastatic lung cancer patients by molecular alteration and response to therapy.
Catherine Labbe , Erin L Stewart , Catherine Brown , Andrea Perez Cosio
Journal of Clinical Oncology 34 6567 -6567
2016
Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.
Vincent K Lam , David S Hong , John Heymach , George R Blumenschein
Journal of Clinical Oncology 36 3056 -3056
4
2018
The effect of prior smoking history on the molecular profile of EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC).
Hadas Sorotsky , Mor Moskovitz , Jessica Weiss , Melania Pintilie
Journal of Clinical Oncology 36 ( 15_suppl) 8533 -8533
2018
A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198.
Stephen KL Chia , Susan Ellard , Mihaela Mates , Stephen Welch
Journal of Clinical Oncology 31 518 -518
1
2013
Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis.
Nathan R. Foster , Lindsay A. Renfro , Steven E. Schild , Mary Weber Redman
Journal of Clinical Oncology 31 7510 -7510
4
2013
Predictors of and longitudinal assessment of health utility scores in patients with small cell lung cancer using real-world data.
Nathan Kuehne , Katrina Hueniken , Wei Xu , Sharara Shakik
Journal of Clinical Oncology 38
2020
Barriers and facilitators to implementation of serial point-of-care hearing tests using a novel iPad-based audiometry in platinum chemotherapy-treated cancer patients (pts).
Spencer Soberano , Khaleeq Khan , Katrina Hueniken , Elyon Diekoloreoluwa Famoriyo
Journal of Clinical Oncology 38 223 -223
2020
EGFR mutations in NSCLC: Does ethnicity influence outcomes?
Pascale Tomasini , Mike Sung , Suzanne Kamel-Reid , Ming Sound Tsao
Journal of Clinical Oncology 33
2015
Phase I/II study of tumor-infiltrating lymphocyte (TIL) infusion and low-dose interleukin-2 (IL-2) in patients with advanced malignant pleural mesothelioma (MPM).
Mark Doherty , Natasha B. Leighl , Ronald Feld , Penelope Ann Bradbury
Journal of Clinical Oncology 33
4
2015
Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone (Ald) serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial.
Jair Bar , Keyue Ding , Huijun Zhao , Scott Andrew Laurie
Journal of Clinical Oncology 31 8048 -8048
2
2013
NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.
Peter Michael Ellis , Geoffrey Liu , Michael Millward , Francesco Perrone
Journal of Clinical Oncology 32 ( 15_suppl) 8036 -8036
10
2014